| 2023-03-04 |
复牌提示：
2023-03-03 19:50:30 停牌，复牌日期 2023-03-07 00:00:01
|
| 2022-11-07 |
详情>>
股本变动：
变动后总股本4793.82万股
|
| 2022-11-07 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.13美元,归母净利润-9018万美元,同比去年增长-105.32%
|
| 2022-11-07 |
财报披露：
美东时间 2022-11-07 盘前发布财报
|
| 2022-08-04 |
详情>>
业绩披露：
2022年中报每股收益-1.59美元,归母净利润-6177.3万美元,同比去年增长-258.23%
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-1.03美元,归母净利润-3772.8万美元,同比去年增长-66.43%
|
| 2022-04-26 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect one Class II Director to our Board of Directors (our “Board”), to serve until our 2025 annual meeting of stockholders;
2.To hold a non-binding, advisory vote on executive compensation;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To approve an amendment to our restated certificate of incorporation, as amended (the “certificate of incorporation”) to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000;
5.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2022-03-03 |
详情>>
业绩披露：
2021年年报每股收益-2.33美元,归母净利润-8005.1万美元,同比去年增长-7.07%
|
| 2021-11-09 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-1.29美元,归母净利润-4392.2万美元,同比去年增长16.14%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-0.51美元,归母净利润-1724.4万美元,同比去年增长48.48%
|
| 2021-05-04 |
详情>>
业绩披露：
2021年一季报每股收益-0.67美元,归母净利润-2266.9万美元,同比去年增长-10.7%
|
| 2021-04-27 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.To elect three Class I Directors to our Board of Directors (our “Board”), to serve until our 2024 annual meeting of stockholders;
2.To hold a non-binding, advisory vote on executive compensation;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2021-02-25 |
详情>>
业绩披露：
2020年年报每股收益-2.4美元,归母净利润-7476.6万美元,同比去年增长4.35%
|
| 2020-11-05 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-1.71美元,归母净利润-5237.6万美元,同比去年增长9.19%
|
| 2020-08-06 |
详情>>
业绩披露：
2020年中报每股收益-1.13美元,归母净利润-3346.8万美元,同比去年增长17.35%
|
| 2020-04-28 |
股东大会：
将于2020-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three Class III Directors to our Board of Directors (our “Board”), to serve until our 2023 annual meeting of stockholders;
2.To hold a non-binding, advisory vote on executive compensation;
3.To hold a non-binding, advisory vote on the frequency of future non-binding, advisory votes on executive compensation;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
5.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2019-04-29 |
股东大会：
将于2019-06-13召开股东大会
会议内容 ▼▲
- 1.The election of two Class II Directors (the “Director Nominees”) to our Board of Directors (the “Board”), to serve until the 2022 annual meeting of stockholders (the “Director Proposal”);
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019 (the “Auditor Proposal”);
3.Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2018-07-09 |
详情>>
内部人交易：
Stuart Nancy共交易2笔
|
| 2018-05-03 |
股东大会：
将于2018-06-14召开股东大会
会议内容 ▼▲
- 1. The election of three Class I Directors (the “Director Nominees”) to our Board of Directors (the “Board”), to serve until the 2021 annual meeting of stockholders (the “Director Proposal”);
2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018 (the “Auditor Proposal”);
3. Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2017-04-26 |
股东大会：
将于2017-05-24召开股东大会
会议内容 ▼▲
- 1. The election of three Class III Directors (the “Director Nominees”) to our Board of Directors (the “Board”), to serve until the 2020 Annual Meeting of Stockholders (the “Director Proposal”);
2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017 (the “Auditor Proposal”);
3. The authorization of the sale (the “Asset Sale”) by the Company to Vertex Pharmaceuticals (Europe) Limited (“Vertex”), a U.K. limited company and wholly-owned subsidiary of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Parent”), of the clinical candidate CTP-656 and other assets related to the treatment of cystic fibrosis pursuant to the terms of the related Asset Purchase Agreement, dated as of March 3, 2017, by and among the Company, Vertex and Parent, as Guarantor (the “Asset Purchase Agreement”), for an aggregate of $160 million in cash upon closing of the transaction (the “Closing”), and an aggregate of up to $90 million following the Closing upon the achievement of certain milestone events (the “Asset Sale Proposal”);
4. The adjournment of the Annual Meeting, if necessary and to the extent permitted by the Asset Purchase Agreement, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the proposals described above (the “Adjournment Proposal”).
|
| 2016-04-25 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1. Election of three Class II Directors to our Board of Directors, to serve until the 2019 Annual Meeting of Stockholders;
2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|
| 2015-04-20 |
股东大会：
将于2015-06-11召开股东大会
会议内容 ▼▲
- 1.Election of three Class I Directors to our Board of Directors, to serve until the 2018 Annual Meeting of Stockholders;
2.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015;
3.Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.
|